Most of what Australians read about human growth hormone comes from two extremes: paediatric endocrinology on one side, and anti-ageing marketing on the other. A newly published phase 3 trial sits awkwardly between them. The foresiGHt trial tested a once-weekly somatropin prodrug in adults with diagnosed growth hormone deficiency against placebo — a design that is rare in this field — and reported a gain of 1.70 kg in total body lean mass over placebo at 38 weeks. If that number sounds familiar, it should. It is roughly the same magnitude that anti-ageing trials produced in healthy older adults who did not have a deficiency at all. That coincidence is the most useful thing in the dataset, and it is worth unpacking carefully if you're doing your own HGH research or trying to understand what human growth hormone actually does.

What foresiGHt actually tested

foresiGHt randomised 259 adults with growth hormone deficiency across 116 centres in North America, Europe and Asia-Pacific, 1:1:1, to once-weekly lonapegsomatropin, once-weekly placebo, or daily somatropin, for 38 weeks. Lonapegsomatropin is not a new hormone — it is a pegylated prodrug that releases unmodified somatropin slowly, so the molecule reaching the receptor is the same one that has been used since the 1980s. What changes is the delivery schedule, not the biology.

At week 38, compared with placebo:

  • Trunk percent fat fell −1.68% versus +0.37% (least-squares mean difference −2.04 percentage points, P < .001) — the primary endpoint
  • Total body lean mass rose +1.60 kg versus −0.11 kg (difference +1.70 kg, P < .0001)
  • Trunk fat mass fell −0.48 kg versus +0.22 kg (difference −0.70 kg, P = .0053)

The trial met its primary endpoint. Safety and tolerability were reported as comparable to daily somatropin. On that basis the weekly product has since gained a US adult growth hormone deficiency indication from the FDA.

The comparison the trial did not make

Here is the detail that gets lost in the headlines: the daily somatropin arm was open-label, and no formal statistical comparison was made between weekly lonapegsomatropin and daily somatropin. The trial was powered against placebo. So "weekly works" is supported; "weekly is better than daily" is not something this trial was designed to answer, and nobody should present it that way. Patient-reported outcomes were an exploratory objective, not a confirmatory one — meaning any quality-of-life improvement is hypothesis-generating rather than proven.

The 1.70 kg problem

Now put that 1.70 kg next to the older literature. In healthy older adults without growth hormone deficiency, GH administration has repeatedly produced roughly 2 kg of lean mass — alongside oedema, joint pain and worsened insulin resistance, with no convincing evidence of improved strength, function or longevity. That is the standing evidence base behind the "anti-ageing" claims, and it has never improved.

So a compound that corrects a genuine pituitary disorder and a compound given to healthy people produce a body-composition shift in the same ballpark. The obvious conclusion: a DEXA change is not evidence that something was wrong with you in the first place. Growth hormone moves fat and water and lean tissue in almost anyone who takes enough of it. What separates the deficient patient from the healthy user isn't the scan — it's that the deficient patient has a diagnosed endocrine disorder in which replacement restores something missing, and is being monitored by an endocrinologist while it happens.

It also explains why "lean mass increased" is such a persistent marketing line. It is true, it is measurable, and it says nothing about whether the person taking it is better off.

Lean mass is not the same as function

Worth stating plainly: neither foresiGHt's primary endpoint nor its key secondary endpoint was a functional outcome. Trunk fat percentage and lean mass are body-composition surrogates. They are reasonable surrogates in diagnosed deficiency, where the metabolic phenotype is well characterised. They are much weaker surrogates for the things people actually want — strength, energy, recovery, healthspan — none of which foresiGHt was built to measure.

HGH Australia: legality, the PBS and where weekly dosing sits

Somatropin is Schedule 4 (prescription only) in Australia and border-controlled. Importing or possessing it without a prescription is illegal, and this is enforced — it is not a grey-area supplement. If you're asking "is HGH legal in Australia", the answer is: legal with a prescription for an approved indication, illegal otherwise.

Access for approved indications runs through the PBS Growth Hormone Program under section 100 of the National Health Act, which subsidises somatropin for defined paediatric conditions and for adults with severe growth hormone deficiency of childhood or adult onset. Treatment must be under an endocrinologist, and diagnosis requires appropriate dynamic testing — a single low IGF-1 does not qualify anyone.

Weekly growth hormone is already part of Australian practice on the paediatric side: somatrogon (Ngenla), a different long-acting GH analogue, has been TGA-registered since 2021 for paediatric growth hormone deficiency and subsequently PBS-listed. The adult weekly indication demonstrated in foresiGHt is a separate regulatory question, and a US approval does not carry over to Australia — the TGA assesses each indication on its own submission.

Finally, growth hormone remains WADA-prohibited at all times, in and out of competition, for every product discussed here. Weekly dosing changes nothing about that status.

You can read the wider profile on our HGH page, compare it with other compounds in the peptides library, or join the free updates list for new trial data as it lands.

What to take from this

foresiGHt is a genuinely good piece of evidence for the population it studied: adults with diagnosed, tested growth hormone deficiency. It is not evidence for growth hormone as a body-recomposition tool in healthy adults — and read alongside the anti-ageing trials, it quietly undermines that case, because the body-composition effect turns out to be roughly the same whether or not there was a deficiency to correct. The presence of a disease, not the presence of an effect, is what makes replacement worth the risk profile.

FAQ

What is weekly HGH?

Weekly HGH refers to long-acting growth hormone products — such as lonapegsomatropin, a pegylated prodrug that slowly releases ordinary somatropin, or somatrogon, a modified GH analogue — designed to be injected once a week instead of daily. The hormone itself is unchanged; only the dosing schedule differs.

Is HGH legal in Australia?

Somatropin is a Schedule 4 prescription-only medicine and a border-controlled substance in Australia. It is legal when prescribed for an approved indication and illegal to import or possess without a prescription.

Is weekly growth hormone better than daily injections?

The foresiGHt trial was powered against placebo, and made no formal statistical comparison between weekly lonapegsomatropin and daily somatropin. It supports weekly dosing as effective, but does not establish that weekly is superior to daily.

Does HGH build muscle in healthy adults?

Trials in healthy older adults have shown around 2 kg of lean mass gain, alongside oedema, joint pain and insulin resistance, without convincing gains in strength or function. Notably, that is a similar magnitude to the 1.70 kg seen in genuinely deficient adults in foresiGHt — so the body-composition change does not indicate a deficiency was present or corrected.

Sources

This article is independent information, not medical advice. Somatropin is TGA-approved and PBS-subsidised in Australia for defined conditions only; it is Schedule 4, border-controlled, and prohibited in sport by WADA. Speak to a qualified Australian health professional about your own situation.